Patents by Inventor Marion E. Perkus

Marion E. Perkus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trova fowl pox virus recombinants comprising heterologous inserts
    Patent number: 5766599
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 16, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
  • Modified recombinant vaccinia virus and expression vectors thereof
    Patent number: 5762938
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: June 9, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
  • Alvac canarypox virus recombinants comprising heterlogous inserts
    Patent number: 5756103
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 26, 1998
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
  • NYVAC vaccinia virus recombinants comprising heterologous inserts
    Patent number: 5494807
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: August 12, 1993
    Date of Patent: February 27, 1996
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe F. Audonnet, Russell R. Gettig
  • Genetically engineered vaccine strain
    Patent number: 5364773
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: November 15, 1994
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus